Estimulação elétrica transcutânea diafragmática pela corrente russa em portadores de DPOC

A doença pulmonar obstrutiva crônica (DPOC) ocasiona prejuízos na mecânica pulmonar, interferindo na atuação, mobilidade e conformidade do diafragma. A estimulação elétrica diafragmática tradicional é capaz de gerar benefícios ao pneumopata; poderia a corrente russa ser outra opção? Objetivou-se identificar as alterações após estimulação diafragmática elétrica transcutânea pela corrente russa em indivíduos portadores de DPOC. Trata-se de estudo prospectivo, quase experimental, com os seguintes critérios de inclusão: estabilidade medicamentosa, cessação tabágica, DPOC grau III e IV e manutenção do estilo de vida. Foram avaliadas medidas antropométricas, respiratórias e funcionais. A estimulação diafragmática se deu pelo Endophasys R ET 9701 por quatro meses, duas vezes por semana, com 30 sessões. O tempo de terapia e frequência para cada sessão foram: 18 min. (20 a 30 Hz) e 12 min. (70 a 100 Hz), respectivamente. Para análise dos dados foi aplicado teste “t” de Student (pLa enfermedad obstructiva crónica (EPOC) perjudica la mecánica pulmonar, interfiriendo en la acción, movilidad y conformidad del diafragma. La estimulación diafragmática eléctrica tradicional es benéfica a los portadores de enfermedades pulmonares, ¿es posible ser otra opción la corriente rusa? El propósito de este trabajo es identificar los resultados tras la estimulación diafragmática eléctrica transcutánea por corriente rusa en pacientes con EPOC. Se trata de un estudio prospectivo, casi experimental, con los siguientes criterios de inclusión: la estabilidad de fármaco, el abandono del tabaco, la EPOC grados III y IV y el mantenimiento del estilo de vida. Se evaluaron medidas antropométricas, respiratorias y funcionales. La estimulación diafragmática fue realizada por el Endophasys R ET 9701 durante cuatro meses, dos veces semanales, con 30 sesiones. El tiempo de terapia y la frecuencia de cada sesión fueron los siguientes: 18 min. (20 a 30 Hz) y 12 min. (70 a 100 Hz), respectivamente. En el análisis de datos se empleó la prueba t de Student (pChronic Obstructive Pulmonary Disease (COPD) causes losses in lung mechanics, interfering in performance, mobility and conformity of the diaphragm, and traditional diaphragmatic electrical stimulation is able to generate benefits to the lung patient. Could Russian current be another option? We aimed to identify changes after transcutaneous diaphragmatic electrical stimulation through the Russian current in individuals with COPD. Prospective and nearly experimental study with inclusion criteria: drug stability, smoking interruption, COPD degrees III and IV and lifestyle maintenance. Anthropometric and functional measurements have been evaluated. Diaphragmatic stimulation occurred by Endophasys R ET 9701 for four months, twice a week, 30 sessions. Therapy time and frequency for each session were: 18 min. (20 to 30 Hz) and 12 min. (70 to 100 Hz), respectively. For data analysis Student’s t-test was applied (

Doença pulmonar obstrutiva crônica

The chronic obstructive lung disease is reviewed with emphasys on its epidemiology and risk factors. The diagnosis, clinical aspects pulmonary, functional alterations and laboratorial findings are discussed. The treatment is also reviewed, based on the actual consensus, considering the following classes of approaches: bronchodilators, inhaled β-agonists, corticoids, methilxanthines, prolonged domiciliar-orygen therapy

Analysis of Plasma Proteins Involved in Inflammation, Immune Response/Complement System, and Blood Coagulation upon Admission of COVID-19 Patients to Hospital May Help to Predict the Prognosis of the Disease

The development of new approaches allowing for the early assessment of COVID-19 cases that are likely to become critical and the discovery of new therapeutic targets are urgently required. In this prospective cohort study, we performed proteomic and laboratory profiling of plasma from 163 COVID-19 patients admitted to Bauru State Hospital (Brazil) between 4 May 2020 and 4 July 2020. Plasma samples were collected upon admission for routine laboratory analyses and shotgun quantitative label-free proteomics. Based on the course of the disease, the patients were divided into three groups: (a) mild (n = 76) and (b) severe (n = 56) symptoms, whose patients were discharged without or with admission to an intensive care unit (ICU), respectively, and (c) critical (n = 31), a group consisting of patients who died after admission to an ICU. Based on our data, potential therapies for COVID-19 should target proteins involved in inflammation, the immune response and complement system, and blood coagulation. Other proteins that could potentially be employed in therapies against COVID-19 but that so far have not been associated with the disease are CD5L, VDBP, A1BG, C4BPA, PGLYRP2, SERPINC1, and APOH. Targeting these proteins’ pathways might constitute potential new therapies or biomarkers of prognosis of the disease